Menu

Top Stories

Published on Thursday, April 11, 2019

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

On April 3, 2019, Francis Collins, MD, PhD, director of the National Institutes of Health (NIH), Mikael Dolsten, MD, PhD, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer, joined in a discussion led by Susan Dentzer, visiting fellow at the Robert J. Margolis Center for Health Policy, Duke University, in Washington DC.

Photo: Francis Collins, MD, PhD, director of the NIH (left) and author Alejandro Hernandez, editorial manager of the Alpha-1 Foundation (right)

For 60 minutes, Collins, Dolsten, and Dentzer engaged in a conversation with the theme of: “Advancing the innovation ecosystem: working together for patients,” where they emphasized the need for continued collaboration between the private and public sectors, along with the patient community, in order to advance new and emerging technologies and innovative approaches for potentially life-saving treatments and new outcomes in medicine.

“We are currently living in remarkable times with amazing things happening in areas such as cancer immuno-therapy, gene therapy, and gene editing. The things that are happening right now, I had no idea they would even be possible just five or six years ago,” expressed Collins when asked about the current position “the ecosystem,” as they described the collaboration between the private and public sectors with small biotech companies; an ecosystem with symbiotic characteristics where all contributors play an important role in a tremendous team effort, in medical research.

Collins and Dolsten agreed on the importance of advocacy groups and organizations as well as the patient community, in being part of the process for better outcomes and the ability to bring new and potential treatments for various conditions to the clinic, including rare diseases, such as Alpha-1 Antitrypsin Deficiency (Alpha-1). 

“We need you, the patient community, you are the reason we have gotten this far,” said Collins.

“One of the most important resources needed for this ecosystem to strive is you, the patient. We need to line-up our resources and keep the ecosystem going, including the patient community. There is no one better to bring together what others (physicians) can do than patients: you inspire all of us,” expressed Dolsten.

The Alpha-1 Foundation applauds and supports these types of initiatives, in which patients become partners and are of vital importance for therapeutic development. 

The panel also mentioned that it is critical to spread awareness and education in the medical community, and being able to have early diagnosis and detection, while mentioning the Accelerating Medicines Partnership (AMP), a public-private partnership between the NIH, the U.S. Food and Drug Administration (FDA), multiple biopharmaceutical, and life science companies, as well as non-profit organizations to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics.

The ultimate goal of AMP is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.

“Patient participation is critical for AMP, especially to remind us what we are doing and why-and-who we are doing it for,” said Collins, who also mentioned the Foundation for the National Institutes of Health (FNIH) as being instrumental in bringing together funds and resources from both the private and public sectors, to work in mutual collaboration in research projects that will ultimately benefit the patient community.

The Alpha-1 Foundation applauds these types of initiatives that support research and bring innovative approaches to the table for the benefit of the patient community, as we are committed to finding a cure for Alpha-1 and improving the lives of Alphas, and those affected by the condition, worldwide.

For more information, please visit the Collaboration Ecosystem website and the AMP website.


Print

Partnership aims at improving donor lung transplant

Wednesday, June 20, 2018
Paragonix Technologies, Inc. entered into a partnership with the Lung Transplant Foundation to support the company’s further development and subsequent commercialization of Paragonix SherpaLung™, a donor lung transport device for...
Divider

Arrowhead completes enrollment in Phase 1 study for treatment of Alpha-1 liver disease

Tuesday, June 19, 2018
Arrowhead Pharmaceuticals, Inc. announced that it has completed enrollment of a Phase 1 clinical trial of ARO-AAT, their second generation subcutaneously administered RNA interference (RNAi) therapeutic that is being developed as a treatment for...
Divider

Alphas will hold one of their biggest meetings in San Francisco

Monday, June 18, 2018
The city of San Francisco, California, will be the site of one of the biggest gatherings of Alphas, when the Alpha-1 Foundation holds, between June 29 – July 1, 2018, its 27th Annual National Education Conference. Alphas – as those...
Divider

New foundation will increase awareness about cell and gene therapy, but caution is recommended

Thursday, June 7, 2018
The Alliance for Regenerative Medicine (ARM) announced the launch of the ARM Foundation for Cell and Gene Medicine, which will be dedicated to increasing public awareness and understanding of the clinical and societal benefits of cell and gene...
Divider

NORD opposes implementation of copay accumulator programs in health plans

Tuesday, June 5, 2018
The National Organization for Rare Disorders (NORD), the nonprofit institution that represents 30 million Americans that suffer from rare diseases, issued the following statement on the increasing use of copay accumulator programs in health...
Divider

RNA interference therapies could be on the verge of success

Tuesday, May 29, 2018
In the mid-2000s there was a wave of excitement across the pharmaceutical industry: a new discovery about cells that had the potential to transform medicine.  “The world became enamored with this idea because it was very powerful. If...
Divider

Consortium seeks common standards for gene-editing therapies

Thursday, May 24, 2018
How to best measure if a therapy is reaching its target gene without introducing errors in others? This is one of the big questions that remain unanswered, as the first CRISPR clinical trials begin in the U.S. and Europe, in 2018. To address...
Divider

2018 research grants on Alpha-1 awarded

Tuesday, May 22, 2018
At a cocktail reception the evening of May 21st, held at The Prado at Balboa Park, within the framework of the American Thoracic Society (ATS) 2018 International Conference in San Diego, California, the Alpha-1 Foundation (A1F) announced the...
Divider

Mark Brantly honored with John W. Walsh PAR Award for Excellence

Monday, May 21, 2018
The Alpha-1 Foundation (A1F) extends a heartfelt message of congratulations to Alpha-1 Antitrypsin Deficiency (Alpha-1) researcher and pioneer, Mark Brantly, MD, for being the first recipient of the newly renamed 2018 John W. Walsh PAR Award for...
Divider

Donohue to receive the Breathing for Life Award

Friday, May 18, 2018
James F. Donohue, MD, will be honored with the Breathing for Life Award at the Tenth Annual American Thoracic Society (ATS) Foundation Research Program Benefit on Saturday, May 19th, 2018, in San Diego, California. The Award is the highest honor...
Divider

Alpha Jonathan Maidment hikes the Pacific Crest Trail

Thursday, May 17, 2018
This story appears in the Spring 2018 issue of Alpha-1-To-One Magazine. Subscriptions are free. Determined and driven are the first two adjectives that come to mind when you get a grasp of the endeavor that 23-year-old Jonathan Maidment has...
Divider

Spring has built new friends to find a cure

Thursday, May 17, 2018
The Building Friends for a Cure (BFC) program was created by the Alpha-1 Foundation (A1F) to make new friends and nurture those friendships throughout the year, because we cannot do it alone, you are all needed! Pictured: George Washington...
Divider
First45678910111213Last

Article Search

Enter keywords in text box and click Search button for results.

Archive